Sign in Create account

Gland Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: GLAND BSE: 543245
₹2899.40
▼ -90.30 (-3.02%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
66/100
Moderate
Valuation
37/100
Fairly Valued
Momentum
50/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹47,828 Cr
PE (TTM)
34.3
Industry median 36.1 (152 companies)
Price to Book
4.6
PEG (TTM)
1.5
Institutions holding %
39.18%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
27.4
Relative return vs Sector, qtr %
17.6
Free Cash Flow
₹541 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
35.31%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
22.76%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
15.86%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
35.33%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
23.85%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
4.68
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.02
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
166.38
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
28.32%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
37.96%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
39.27%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
8.21%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
13.74%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
9.92%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 8 met
  • Yes Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.02)
  • No Return on equity is 15% or more (9.9%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.0%
Low 2872.0000 · High 3007.7000
1W return
-0.4%
Low 2872.0000 · High 3024.0000
1M return
0.5%
Low 2792.4000 · High 3042.0000
52W return
46.3%
Low 1573.6000 · High 3042.0000
Lifetime High ₹4316.2500 (Aug. 12, 2021)
Lifetime Low ₹893.5500 (May 22, 2023)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
2923.2
10D
2921.0
20D
2906.3
50D
2786.8
100D
2570.0
200D
2142.3

Delivery and volume

Day avg. delivery
56.4%
Week avg. delivery
52.5%
Month avg. delivery
70.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

2926.37
Pivot
First resistance2980.73
Second resistance3062.07
Third resistance3116.43
First support2845.03
Second support2790.67
Third support2709.33
Day RSI51.3
Day MFI42.4
Day MACD31.05
Day MACD signal41.50

Beta

1M0.18
3M0.48
1Y0.59
3Y0.65

Price change analysis

↑ 0.5%
Over 1 Month
LowHigh
2792.403042.00
↑ 17.6%
Over 3 Months
LowHigh
2351.103042.00
↑ 70.0%
Over 6 Months
LowHigh
1652.003042.00
↑ 46.3%
Over 1 Year
LowHigh
1573.603042.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 34.3 (own history: 21.5–29.5)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹1,287 Cr
Net profit (June 30, 2026)
₹364 Cr
Basic EPS (June 30, 2026)
₹22.1100

Ranks #17 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter51.77%
  • Mutual funds28.23%
  • FII/FPI8.74%
  • Other DII2.21%
  • Public9.05%

Largest holders

NameCategoryShares %Shares
Fosun Pharma Industrial Pte. LtdPromoter51.7700%85393894
Hdfc Mutual Fund - Hdfc Mid-Cap FundPublic6.1100%10079938
Mirae Asset Large & Midcap FundPublic5.6900%9378765
Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap FundPublic4.9300%8131364
Sbi Large & Midcap FundPublic3.3200%5484673

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 51.83% to 51.77% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 7.30% to 8.74% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 31.78% to 28.23% in Jun 2026 qtr

43 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 467 insider trades, 18 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
11 Feb 2026 A. JAYATHEERTHA Employee / designated person Sell 0 ₹0
5 Feb 2026 A. JAYATHEERTHA Employee / designated person Sell 0 ₹0
5 Feb 2026 P LAKSHMI NARAYANA Employee / designated person Sell 0 ₹0
25 Nov 2025 P LAKSHMI NARAYANA Employee / designated person Sell 0 ₹0
29 Sep 2025 A. JAYATHEERTHA Employee / designated person Sell 0 ₹0
29 Sep 2025 A. JAYATHEERTHA Employee / designated person Sell 0 ₹0
26 Feb 2025 S SRINIVASA RAO Employee / designated person Buy 0 ₹0
28 Jun 2024 RONG WU Employee / designated person Sell 0 ₹0
28 Jun 2024 S SRINIVASA RAO Employee / designated person Sell 0 ₹0
28 Jun 2024 P B Ravindra Varma Employee / designated person Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 34 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
17 Sep 2026 NORTH ROCK SG VCC Block Sell 150,000 2826.6000 NSE
17 Sep 2026 BOFA SECURITIES EUROPE SA Block Buy 150,000 2826.6000 NSE
17 Sep 2026 NORTH ROCK SG VCC Block Sell 150,000 2826.6000 NSE
17 Sep 2026 BOFA SECURITIES EUROPE SA Block Buy 150,000 2826.6000 NSE
4 Sep 2026 ADITYA BIRLA SUN LIFE MUTUAL FUND Block Buy 90,000 2826.6000 BSE
4 Sep 2026 FOSUN PHARMA INDUSTRIAL PTE. LTD. Block Sell 90,000 2826.6000 BSE
4 Sep 2026 SUNDARAM MUTUAL FUND Block Buy 170,000 2826.6000 BSE
4 Sep 2026 MIRAE ASSET MUTUAL FUND Block Buy 175,000 2826.6000 BSE
4 Sep 2026 KOTAK MAHINDRA LIFE INSURANCE COMPANY LIMITED Block Buy 250,000 2826.6000 BSE
4 Sep 2026 NRSGVCC Block Buy 270,000 2826.6000 BSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹20.00 per share
Dividend yield 0.69%
Ex-dateSubjectPer share (₹)Record date
11 Aug 2026 Dividend - Rs 20 Per Sh 20.0000 11 Aug 2026
14 Aug 2025 Dividend - Rs 18 Per Share 18.0000 14 Aug 2025
16 Aug 2024 Annual General Meeting/Dividend - Rs 20 Per Share 20.0000 16 Aug 2024

Corporate Actions

Full history (4 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
6 Aug 2021OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
10 Aug 2026 Financial Results Yes
15 May 2026 Financial Results/Dividend Yes
28 Jan 2026 Financial Results Yes
3 Nov 2025 Financial Results Yes
5 Aug 2025 Financial Results Yes

Corporate Announcements

All 700 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 Company Update Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Directorate
1 Oct 2026 Company Update Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
1 Oct 2026 Insider Trading / SAST Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
1 Oct 2026 Others Gland Pharma Ltd - 543245 - Board Meeting Outcome for Outcome Of Board Meeting - 01-10-2026
1 Oct 2026 Resignation of Director/KMP/SMP Gland Pharma Limited has informed the Exchange about Resignation of Director/KMP/SMP
1 Oct 2026 General Updates Gland Pharma Limited has informed the Exchange about Investment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc.
1 Oct 2026 Outcome of Board Meeting Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026.
30 Sep 2026 Insider Trading / SAST Gland Pharma Ltd - 543245 - Closure of Trading Window
30 Sep 2026 Insider Trading / SAST Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
30 Sep 2026 Trading Window Gland Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (28.3%)
  • Low financial leverage (Debt/Equity 0.02)
  • Comfortable interest coverage (166.4x)
  • Strong revenue growth YoY (23.9%)

Weaknesses

  • Low Return on Equity (9.9%)

Opportunities

Data unavailable.

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Part of: NIFTY 500, NIFTY 500, NIFTY MNC, NIFTY MNC, NIFTY PHARMA, NIFTY PHARMA

Frequently asked questions about Gland Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.